Theriva Biologics reported Q1 2026 results highlighting FDA alignment on the Phase 3 trial design for VCN-01, a cancer drug targeting metastatic pancreatic ductal adenocarcinoma (PDAC). New data from the Phase 2b VIRAGE trial suggest VCN-01 may work through an immune-mediated mechanism, improving survival and tumor response, especially with repeated dosing. The company plans a dosing feasibility study in Spain and is advancing a potential Phase 2/3 trial for retinoblastoma using VCN-01 with topotecan. Cash reserves stand at $14.4 million, supporting operations into Q1 2027.
Hilton Worldwide Holdings Inc. reported strong Q2 2026 results, with earnings per share of $2.29 surpassing analyst estimates of $2.27 and revenue of $3.34 billion beating the $3.32 billion forecast. The company showed growth from the previous year, ...
Apptopia's report reveals that Roblox Corporation experienced growth in Weekly Active Users and average time spent per daily active user among the 17-25 age group during Q2 2026, continuing into July. This trend highlights increasing engagement from ...
LEPAS, Chery Auto's mid-to-premium new energy vehicle (NEV) brand, has introduced a global lineup featuring the LEPAS L4 EV, L6 EV, and L8 PHEV. These models emphasize elegant design, intelligent technology, and versatile space to meet diverse global...
Implicity received FDA clearance for its next-generation ILR ECG Analyzer, an AI-powered cloud software that reduces false-positive alerts from implantable cardiac monitors by up to 76% while maintaining high sensitivity for true cardiac events. The ...
YieldMax ETFs announced weekly distributions for their Group 1 ETFs, with distribution rates ranging from 26.17% to 60.34% annualized. These ETFs cover sectors like semiconductors, AI & tech, crypto, metals, and covered call strategies. Distributions...
